4D Molecular Therapeutics (FDMT) Current Leases (2021 - 2026)

4D Molecular Therapeutics (FDMT) has reported Current Leases for 6 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases fell 3.4% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $5.5 million (down 3.4% YoY), while the FY2025 annual figure was $5.6 million, down 0.8% from the prior year.
• Current Leases slipped to $5.5 million in Q1 2026 per FDMT's latest filing, from $5.6 million in the prior quarter.
• Across five years, Current Leases topped out at $5.7 million in Q2 2025 and bottomed at $2.0 million in Q1 2022.
• Historically, Current Leases has averaged $4.0 million across 5 years, with a median of $3.2 million in 2024.
• Annual changes were most pronounced in 2022 — Current Leases jumped 115.68% — and 2026, when it slipped 3.4%.
• 4D Molecular Therapeutics' Current Leases stood at $2.7 million in 2022, then grew by 18.61% to $3.1 million in 2023, then surged by 79.01% to $5.6 million in 2024, then slipped by 0.8% to $5.6 million in 2025, then slipped by 1.9% to $5.5 million in 2026.
• Business Quant data shows FDMT's Current Leases at $5.5 million in Q1 2026, $5.6 million in Q4 2025, and $5.7 million in Q3 2025.